Evaluation of medication use in Malaysian predialysis patients

Abstract EN

Chronic kidney disease (CKD) patients suffer from multiple comorbidities and complications as a cause or consequence of kidney disease.

Information regarding medicationprescribing patterns in predialysis patients is sparse.

We conducted a retrospective study to evaluate the medication prescription patterns among predialysis patients.

Medical records (both paper based and computerized) of patients at CKD Resource Centre, Hospital Universiti Sains Malaysia, were reviewed.

A total of 615 eligible cases were included in the study.

The mean number of medications prescribed per patient was 8.22 ± 2.81, and medication use was correlated to the renal function (stage 3a < stage 3b < stage 4 < stage 5; P <0.001).

The top three prescribed medication groups were found to be lipid-lowering agents, calcium channel blockers, and antiplatelet agents.

Some medication classes such as nonaluminum/noncalcium phosphate binders, erythropoietin-stimulating agents, and renin-angiotensin-aldosterone system blockers, particularly in advanced stage, were found to be underutilized.

In conclusion, predialysis patients are prescribed a large number of medications.

Our findings highlight the need for assessing the impact of current medication-prescribing patterns on morbidity and mortality rates in Malaysian predialysis population.